Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - SKINVISIBLE INCFinancial_Report.xls
EX-32.1 - EX32_1 - SKINVISIBLE INCex32_1.htm
EX-31.1 - EX31_1 - SKINVISIBLE INCex31_1.htm
EX-31.2 - EX31_2 - SKINVISIBLE INCex31_2.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

[X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
   
  For the quarterly period ended September 30, 2014
   
[  ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934
   
  For the transition period from __________  to __________
   
  Commission File Number: 000-25911

 

Skinvisible, Inc.

(Exact name of Registrant as specified in its charter)

 

Nevada 88-0344219
(State or other jurisdiction of incorporation or organization)  (IRS Employer Identification No.)

 

6320 South Sandhill Road, Suite 10, Las Vegas, NV 89120
(Address of principal executive offices)

 

702.433.7154
(Registrant’s telephone number)
 
 _______________________________________________________________
(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days

[X] Yes [ ] No

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

   
[  ] Large accelerated filer [  ] Accelerated filer
[  ] Non-accelerated filer [X] Smaller reporting company

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

[ ] Yes [X] No

 

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 111,741,969 common shares as of October 31, 2014

 

 

 

 

  TABLE OF CONTENTS

 

Page

 

PART I – FINANCIAL INFORMATION

 

Item 1: Financial Statements  3
Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations  4
Item 3: Quantitative and Qualitative Disclosures About Market Risk  10
Item 4: Controls and Procedures  11

 

PART II – OTHER INFORMATION

 

Item 1: Legal Proceedings  11
Item 1A: Risk Factors  11
Item 2: Unregistered Sales of Equity Securities and Use of Proceeds  12
Item 3: Defaults Upon Senior Securities  12
Item 4: Mine Safety Disclosure  12
Item 5: Other Information  12
Item 6: Exhibits  12

 

2

 

PART I - FINANCIAL INFORMATION

 

Item 1.     Financial Statements

 

Our consolidated financial statements included in this Form 10-Q are as follows:

 

F-1 Consolidated Balance Sheets as of September 30, 2014 and December 31, 2013 (unaudited);
F-2 Consolidated Statements of Operations for the three and nine months ended September 30, 2014 and 2013 (unaudited);
F-3 Consolidated Statements of Cash Flow for the nine months ended September 30, 2014 and 2013 (unaudited);
F-4 Notes to Consolidated Financial Statements.

 

These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10-Q.  In the opinion of management, all adjustments considered necessary for a fair presentation have been included.  Operating results for the interim period ended September 30, 2014 are not necessarily indicative of the results that can be expected for the full year.

 

3

 

SKINVISIBLE, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited) 

 

  September 30, 2014  December 31, 2013
ASSETS      
Current assets          
Cash  $258,306   $513,420 
Accounts receivable   20,621    11,591 
Inventory   81,830    22,437 
Due from related party   1,145    1,145 
Prepaid expense and other current assets   514    515 
Total current assets   362,416    549,108 
Fixed assets, net of accumulated depreciation of $323,880 and  $322,813, respectively   3,670    3,555 
Intangible and other assets:          
Patents and trademarks, net of accumulated amortization of $276,024 and $249,064, respectively   309,101    321,388 
Total assets  $675,187   $874,051 
LIABILITIES AND STOCKHOLDERS' DEFICIT          
Current liabilities          
Accounts payable and accrued liabilities  $411,141   $479,622 
Accrued interest payable   298,713    165,197 
Loans from related party   1,910    1,832 
Loans payable   1,594,400    1,000,000 
Convertible notes payable, net of unamortized debt discount of $37,192 and $66,490, respectively   1,107,394    1,091,097 
Convertible notes payable related party, net of unamortized discount of $896,522 and $949,672, respectively   1,085,523    873,689 
Total current liabilities   4,499,081    3,611,437 
Total liabilities   4,499,081    3,611,437 
Stockholders' deficit          
Common stock; $0.001 par value; 200,000,000 shares authorized; 111,569,969 and 110,909,969 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively   111,570    110,910 
Additional paid-in capital   21,285,657    21,066,512 
Stock payable   —      —   
Accumulated deficit   (25,221,121)   (23,914,808)
Total stockholders' deficit   (3,823,894)   (2,737,386)
Total liabilities and stockholders' deficit  $675,187   $874,051 

 

See Accompanying Notes to Consolidated Financial Statements. 

 

F-1

 

SKINVISIBLE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

  Three Months Ending  Nine Months Ending
  September 30, 2014  September 30, 2013  September 30, 2014  September 30, 2013
Revenues  $22,303   $13,635   $41,276   $48,370 
Cost of revenues   674    565    3,907    1,754 
Gross profit   21,629    13,070    37,369    46,616 
Operating expenses                    
Depreciation and amortization   9,680    9,824    28,027    27,006 
Selling general and administrative   373,101    220,021    758,997    616,167 
Total operating expenses   382,781    229,845    787,024    643,173 
Loss from operations   (361,152)   (216,775)   (749,655)   (596,557)
Other income and (expense)                    
Other income   70    97    258    97 
Interest expense   (200,944)   (125,825)   (551,872)   (436,398)
Gain (loss) on extinguishment of debt   (4,054   2,400    (5,044)   3,100 
Total other expense   (204,928)   (123,328)   (556,658)   (433,201)
Net loss  $(566,080)  $(340,103)  $(1,306,313)  $(1,029,758)
Basic loss per common share  $(0.01)  $(0.00)  $(0.01)  $(0.01)
Basic weighted average common shares outstanding   111,609,529    110,683,012    111,317,222    110,374,484 

 

See Accompanying Notes to Consolidated Financial Statements.

 

F-2

 

SKINVISIBLE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOW

(Unaudited)

 

  Nine Months Ended
  September 30, 2014  September 30, 2013
Cash flows from operating activities:          
Net loss  $(1,306,313)  $(1,029,758)
 Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   28,027    27,006 
Stock-based compensation   31,050    21,200 
Amortization of debt discount   250,558    228,244 
Stock issued for interest expense   —      422 
Loss on extinguishment of debt   5,044    3,100 
Changes in operating assets and liabilities:          
(Increase) decrease in inventory   (59,393)   (3,668)
Decrease in accounts receivable   (9,030)   17,299 
Increase in prepaid expenses and other current assets   1    (500)
Increase (decrease) in accounts payable and accrued liabilities   105,803    69,776 
Increase in accrued interest   133,516    105,099 
Decrease in unearned revenue   —      (19,792)
Net cash used in operating activities   (820,737)   (581,572)
Cash flows from investing activities:          
Purchase of fixed assets and intangible assets   (15,855)   (120,575)
Net cash used in investing activities   (15,855)   (120,575)
Cash flows from financing activities:          
Proceeds from, net of payments to, related parties for loans   78    (7,527)
Payments on related parties convertible notes payable   —      (12,475)
Advances to related parties   —      (40,043)
Proceeds from convertible notes payable   —      —   
Payments on convertible notes payable   (13,000)   (14,000)
Proceeds from loans payable   594,400    1,000,000 
Payments on loans payable   —      —   
Net cash provided by (used in) financing activities   581,478    925,955 
Net change in cash   (255,114)   223,808 
Cash, beginning of period   513,420    450,507 
Cash, end of period  $258,306   $674,315 
Supplemental disclosure of cash flow information:          
Cash paid for interest  $144,708   $97,194 
Cash paid for tax  $—     $—   
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:          
Non-cash investing and financing activities:          
Common stock issued on conversion of debts  $—     $23,554 
Accrued expenses converted to notes  $158,684   $—   
Loan payable converted to convertible loan  $—     $23,554 
Common stock issued on extinguishment of debts  $20,644   $16,100 

 

See Accompanying Notes to Consolidated Financial Statements.

 

F-3

 

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

1. DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES

 

Description of business – Skinvisible, Inc., (referred to as the “Company”) is focused on the development and manufacture of innovative topical, transdermal and mucosal polymer-based delivery system technologies and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Additionally, the Company’s non-dermatological formulations, offer solutions for a broad spectrum of markets women’s health, pain management, and others. The Company maintains executive and sales offices in Las Vegas, Nevada.

 

History – Skinvisible, Inc. (referred to as the “Company”) was incorporated in Nevada on March 6, 1998, under the name of Microbial Solutions, Inc. The Company underwent a name change on February 26, 1999, when it changed its name to Skinvisible, Inc. The Company’s subsidiary’s name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals, Inc.

 

Skinvisible, Inc. together with its subsidiary shall herein be collectively referred to as the “Company”.

 

Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of $25,221,121 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

 

Principles of consolidation – The consolidated financial statements include the accounts of the Company and its subsidiary. All significant intercompany balances and transactions have been eliminated.

 

Use of estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash and cash equivalents For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents. There are $258,306 and $513,420 in cash and cash equivalents as of September 30, 2014 and December 31, 2013, respectively.

 

Fair Value of Financial Instruments

The carrying amounts reflected in the balance sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these items.

 

As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

 

The three levels of the fair value hierarchy are described below:

 

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

 

Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

 

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

 

F-4

 

Revenue recognition

 

Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.

 

Royalty sales – The Company also recognizes royalty revenue from licensing its patented product formulations only when earned, when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

 

Distribution and license rights sales – The Company also recognizes revenue from distribution and license rights only when earned (and are amortized over a five year period), when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

 

Costs of Revenue – Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

 

Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of September 30, 2014, the Company had not recorded a reserve for doubtful accounts. The Company has $1,000,000 in convertible notes payable which are secured by the accounts receivable of a license agreement the Company has with Women's Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®.

 

Inventory – Substantially all inventory consists of finished goods and are valued based upon first-in first-out ("FIFO") cost, not in excess of market. The determination of whether the carrying amount of inventory requires a write-down is based on an evaluation of inventory.

 

Goodwill and intangible assets – The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “Intangibles – Goodwill and Other”. According to this statement, goodwill and intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Fair value for goodwill is based on discounted cash flows, market multiples and/or appraised values as appropriate. Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.

 

Income taxes – The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

  

Stock-based compensation – The Company follows the guidelines in FASB Codification Topic ASC 718-10 “Compensation-Stock Compensation”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to a Employee Stock Purchase Plan based on the estimated fair values.

 

Stock based compensation expense recognized under ASC 718-10 for the nine months ended September 30, 2014 and 2013 totaled $31,050  and $21,200, respectively.

 

Earnings (loss) per share – The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “Earnings Per Share”, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect.

 

F-5

 

2. FIXED ASSETS

 

Fixed assets consist of the following as of September 30, 2014 and December 31, 2013:

 

  September 30, 2014  December 31, 2013
Machinery and equipment  $48,163   $48,163 
Furniture and fixtures   113,635    113,635 
Computers, equipment and software   39,722    38,540 
Leasehold improvements   12,569    12,569 
Lab equipment   113,461    113,461 
 Total   327,550    326,368 
Less: accumulated depreciation   (323,880)   (322,813)
Fixed assets, net of accumulated depreciation  $3,670   $3,555 

 

Depreciation expense for the nine months ended September 30, 2014 and 2013 was $1,067 and $1,003 respectively.

 

3. INVENTORY

 

Inventory consist of the following as of September 30, 2014 and December 31, 2013:

 

  September 30, 2014  December 31, 2013
Finished Goods  $19,700   $5,955 
Raw Materials   62,130    16,482 
 Total   81,830    22,437 

 

4.    INTANGIBLE AND OTHER ASSETS

 

Patents and trademarks are capitalized at their historical cost and are amortized over their estimated useful lives. As of September 30, 2014, patents and trademarks total $585,125, net of $276,024 of accumulated amortization. Amortization expense for the nine months ended September 30, 2014 and 2013 was $26,960 and $26,003 respectively.

 

License and distributor rights (“agreement”) were acquired by the Company in January 1999 and provide exclusive use distribution of polymers and polymer based products. The Company has a non-expiring term on the license and distribution rights. Accordingly, the Company annually assesses this license and distribution rights for impairment and has determined that no impairment write-down is considered necessary as of September 30, 2014.

  

5.    UNEARNED REVENUE

 

On January 16, 2013, the company terminated its licensing agreement with Panalab dated January 23, 2008. The agreement provided Panalab the right to distribute, market, sell and promote Skinvisible’s proprietary formulas made with Invisicare and Adapalene through-out Panalabs assigned territory. Panalab had failed to sell or sub-license the products in the territory, thereby not fulfilling the conditions as set forth in the agreement and allowing for immediate termination of the agreement. As a result of this cancelation, unearned revenue of $19,792 was recognized as revenue during the year ended December 31, 2013.

 

F-6

 

6. STOCK OPTIONS AND WARRANTS

 

The following is a summary of option activity during the nine months ended September 30, 2014.

 

  Number of Shares  Weighted Average Exercise Price
Balance, December 31, 2013   9,300,000   $0.05 
Options granted and assumed   —      —   
Options expired   —      —   
Options canceled   —      —   
Options exercised   —      —   
Balance, September 30, 2014   9,300,000   $0.05 

 

As of September 30, 2014, 9,300,000 stock options are exercisable.

 

On September 23, 2013, the Company granted stock options for 300,000 shares of its common stock with a strike price of $0.03. The stock options were exercisable upon grant and have a life of 5 years. The stock options were valued at $8,400 using the Black-Scholes option pricing model based upon the following assumptions: term of 5 years,  risk free interest rate of 1.33%, a dividend yield of 0% and volatility rates of 443%.   The Company recorded an expense of $8,400 for the year ended December 31, 2013.

 

Stock warrants -

 

The following is a summary of warrants activity during the nine months ended September 30, 2014.

 

  Number of Shares  Weighted Average Exercise Price
Balance, December 31, 2013   3,818,780   $0.05 
Warrants granted and assumed   700,000    0.04 
Warrants expired   787,500    0.06 
Warrants canceled   —      —   
Warrants exercised   —      —   
Balance, September 30, 2014   3,731,280   $0.05 

 

 

F-7

 

All warrants outstanding as of September 30, 2014 are exercisable.

 

On February 11, 2013, the Company issued a warrant for 180,915 shares of common stock to the note holder with a exercise price of $0.05. The vesting period on these grant was immediate. The value of these warrants were estimated by using the Black-Scholes option pricing model with the following assumptions: expected life of 2 years; risk free interest rate of 0.27%; dividend yield of 0% and expected volatility of 178%. To account for such grants to non-employees, we recorded the issuance as consulting expense in the amount of $1,683.

 

On February 11, 2013, the Company issued a warrant for 90,365 shares of common stock to a note holder with a exercise price of $0.05. The vesting period on these grant was immediate. The value of these warrants were estimated by using the Black-Scholes option pricing model with the following assumptions: expected life of 2 years; risk free interest rate of 0.27%; dividend yield of 0% and expected volatility of 178%. To account for such grants to non-employees, we recorded the issuance as consulting expense in the amount of $840.

 

On May 22, 2013, the Company issued a warrant for 200,000 shares of common stock to Retire Happy, LLC for Consulting services. The warrants have an exercise price of $0.04 and the vesting period on these grants was immediate. The value of these warrants were estimated by using the Black-Scholes option pricing model with the following assumptions: expected life of 1 years; risk free interest rate of 0.11%; dividend yield of 0% and expected volatility of 167%. To account for such grants to non-employees, we recorded the issuance as consulting expense in the amount of $3,000.

 

On May 20, 2014, the Company issued a warrant for 200,000 shares of common stock to Retire Happy, LLC for Consulting services. The warrants have an exercise price of $0.02 and the vesting period on these grants was immediate. The value of these warrants were estimated by using the Black-Scholes option pricing model with the following assumptions: expected life of 1 years; risk free interest rate of 0.09%; dividend yield of 0% and expected volatility of 292%. To account for such grants to non-employees, we recorded the issuance as consulting expense in the amount of $4,600.

 

On August 20, 2014, the Company issued a warrant for 500,000 shares of common stock to Retire Happy, LLC for Consulting services. The warrants have an exercise price of $0.04 and the vesting period on these grants was immediate. The value of these warrants were estimated by using the Black-Scholes option pricing model with the following assumptions: expected life of 1 years; risk free interest rate of 0.012%; dividend yield of 0% and expected volatility of 217%. To account for such grants to non-employees, we recorded the issuance as consulting expense in the amount of $26,450.

 

7. NOTES PAYABLE

 

On May 22, 2013 the Company approved a financing plan to offer accredited investors up to $1,000,000 in secured promissory notes. During the nine months ended September 30, 2013 the Company entered into twenty-four 9% notes payable to investors and received total proceeds of $1,000,000. The notes are due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods".

 

On May 19, 2014 the Company approved a financing plan to offer accredited investors up to an additional $1,000,000 in secured promissory notes. For the period from May 19, 2014 to September 30, 2014 the Company entered into fourteen 9% notes payable to investors and received total proceeds of $594,400. The notes are due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods".

 

8.    RELATED PARTY TRANSACTIONS

 

During the year ended 2013 various officers advanced funds to support the daily operations of the company. As of September 30, 2014, $1,910 remained due to related parties as repayment for advanced monies, all related other party notes have been extinguished or re-negotiated as convertible notes. See note 10.

  

F-8

 

9. CONVERTIBLE NOTES PAYABLE

 

Convertible Notes Payable at consists of the following:  September 30,  December 31,
   2014  2013
$52,476 face value,10% unsecured note payable to an investor, note interest and payment are due on demand.  The note could be converted to option rights for Skinvisible, Inc. shares at ten cents per share ($0.10), these rights expired January 12, 2010. Note is currently in default, no penalties occur due to default.  $33,476   $36,476 
$27,000 face value 10% unsecured notes payable to investors, due October, 2012.  At the written request of the investor’s until the repayment date, the note may be converted at the investors option to shares of the Company’s common stock at a fixed price of $0.05 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.07 per share for two years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $19,385. The aggregate beneficial conversion feature was accreted and charged to interest expenses as a financing expense in the amount of $19,385 in the year ending December 31, 2012.  The beneficial conversion feature is valued under the intrinsic value method.  Interest due to lender can also be converted at a rate of ($0.05) per share into warrants.   —      10,000 
$1,000,000 face value 9% unsecured notes payable to investors, due in 2015.  At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of  90% of the current share price after the first anniversary of the note. The Notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company has determined the value associated with the beneficial conversion feature in connection with the notes and interest to be $111,110. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $36,776 during the nine months ended September 30, 2014.  The original issue discount feature is valued under the intrinsic value method.   1,000,000    1,000,000 
Original issue discount   111,110    111,110 
Unamortized debt discount   (37,192)   (66,490)
   $1,107,394   $1,091,097 

 

F-9

 

10. CONVERTIBLE NOTES PAYABLE RELATED PARTY

 

Convertible Notes Payable Related Party at consists of the following:  September 30,  December 31,
   2014  2013
On December 31, 2011, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, the notes dated before December 31, 2010, and all salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on December 31, 2011 to be $1,123,078. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $125,916 during the nine months ending September 30, 2014.  The beneficial conversion feature is valued under the intrinsic value method.  In the year ending December 2013, the Company  made $51,485 in cash payments to reduce the note balance.   1,071,593    1,071,593 
Unamortized debt discount   (374,077)   (499,993)
On June 30, 2012, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, the notes dated before July 1, 2011, and all salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the  notes to be $209,809. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $31,443 during the nine months ending September 30, 2014.  The beneficial conversion feature is valued under the intrinsic value method.  On January 18, 2013, the Company  made a $3,990 cash payment to reduce the note balance.   321,032    321,032 
Unamortized debt discount   (114,019)   (145,462)

 

F-10

 

On December 30 and 31, 2012, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements,  $182,083 of related party notes accrued interest and salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $182,083 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $182,083. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $27,525 during the nine months ending September 30, 2014.  The beneficial conversion feature is valued under the intrinsic value method.   182,083    182,083 
Unamortized debt discount   (118,147)   (145,672)
On June 30, 2013, the Company re-negotiated accrued salaries and interest for two employees. Under the terms of the agreements,  $106,153 of accrued interest and salaries were converted to promissory notes convertible into common stock with a warrant feature. The $106,153 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $70,768. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $10,698 during the nine months ending September 30, 2014.  The beneficial conversion feature is valued under the intrinsic value method.   106,152    106,152 
Unamortized debt discount   (52,938)   (63,636)
 
On December 31, 2013, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, $142,501 of accrued interest and salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $142,501 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $94,909. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $10,209 during the nine months ending September 30, 2014. The beneficial conversion feature is valued under the intrinsic value method.
   142,501    142,501 
Unamortized debt discount   (84,700)   (94,909)

 

F-11

 

On June 30, 2014, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements,  $118,126 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $118,126 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.025 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.03 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $118,126. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $5,951 during the nine months ending September 30, 2014.   The beneficial conversion feature is valued under the intrinsic value method.   118,126    —   
Unamortized debt discount   (112,175)   —   
On September 30, 2014, the Company re-negotiated accrued salaries and interest for two employees. Under the terms of the agreements,  $40,558 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $40,558 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.05 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $40,466. The aggregate beneficial conversion feature will be accreted and charged to interest expenses as a financing expense.  The beneficial conversion feature is valued under the intrinsic value method.   40,558    —   
Unamortized debt discount   (40,466)   —   
   $1,085,523   $873,689 

 

F-12

 

11. STOCKHOLDERS’ DEFICIT

 

The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. The Company had 111,569,969 and 110,909,969 issued and outstanding shares of common stock as of September 30, 2014 and December 31, 2013, respectively.

 

On January 7, 2014 the Company issued 180,000 shares with a fair value of $5,400 to settle $3,600 in outstanding accounts payable. As a result of this transaction a loss on extinguishment of debt of $1,800 was recognized.

 

On April 3, 2014 the Company issued 180,000 shares with a fair value of $2,790 to settle $3,600 in outstanding accounts payable. As a result of this transaction a gain on extinguishment of debt of $810 was recognized.

 

On July 1, 2014 the Company issued 140,000 shares with a fair value of $5,614 to settle $3,600 in outstanding accounts payable. As a result of this transaction a loss on extinguishment of debt of $2,014 was recognized.

 

On July 7, 2014 the Company issued 80,000 shares with a fair value of $3,400 to settle $2,400 in outstanding accounts payable due to a consultant for research and development services. As a result of this transaction a loss on extinguishment of debt of $1,000 was recognized.

 

On August 4, 2014 the Company issued 80,000 shares with a fair value of $3,440 to settle $2,400 in outstanding accounts payable due to a consultant for research and development services. As a result of this transaction a loss on extinguishment of debt of $1,040 was recognized.

 

During the year ended December 31, 2013, the Company issued a total of 1,402,560 shares of common stock, with a fair value of $44,554 for the conversion of outstanding debts of $37,567, related interest of $1,277 and settlement of stock payable $1,800. The Company recorded a gain of $3,910 on extinguishment of debts.

 

12. COMMITMENTS AND CONTINGENCIES

 

Lease obligations – The Company has operating leases for its offices. Future minimum lease payments under the operating leases for the facilities as of September 30, 2014, are as follows:

 

2014 10,392

2015 5,526

 

Rental expense, resulting from operating lease agreements, approximated $31,368 and $14,982 for the nine months ended September 30, 2014 and 2013, respectively.

 

13.  DEFINITIVE AGREEMENTS

 

On January 16, 2013, the company terminated its licensing agreement with Panalab dated January 23, 2008. The agreement provided Panalab the right to distribute, market, sell and promote the Skinvisible’s proprietary formulas made with Invisicare and Adapalene through-out Panalabs assigned territory. Panalab had failed to sell or sub-license the products in the territory, thereby not fulfilling the conditions as set forth in the agreement and allowing for immediate termination of the agreement. . As a result of this cancelation the deferred revenue of $19,792 was recognized as revenue in the in the nine month period ended September 30, 2013.

 

14. SUBSEQUENT EVENTS

 

During the month ended October 2014 the Company entered into 2 9% notes payable to investors and received total proceeds of $50,000. The notes are, due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods".

  

F-13

 

Item 2.     Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.   These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions.  We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions.  Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.  Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.  We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

 

Company Overview

 

We, through our wholly owned subsidiary Skinvisible Pharmaceuticals Inc., are a pharmaceutical research and development (“R&D”) company that has developed and patented an innovative polymer delivery system, Invisicare® and formulated over forty topical skin products, which we out-license globally. We were incorporated in 1998, and target an estimated $80 billion global skincare and dermatology market and a $30 billion global over-the-counter market as well as other healthcare / medical and consumer goods markets.

 

With the research and development complete on forty products and numerous patents issued (technology and product patents), we are ready to monetize our investment. Our business model will continue to be to out-license our patented prescription and over-the-counter (“OTC”) products featuring Invisicare to established manufacturers and marketers of brands internationally and to maximize profits from the products we have already out-licensed. We have also formed a commercial subsidiary, Kintari USA Inc., in order to take our cosmeceutical and select OTC products with Invisicare to market.

 

The opportunity for us to license our products continues to be a viable model as the need for pharmaceutical companies to access external R&D companies for new products due to their own down-sizing or elimination of internal R&D departments. The demand for our products is enhanced due to the granting of key US and international patents and the completed development of a number of unique products.




 




4

 

Our Plan for the Next Twelve Months

 

Our growth strategy is to:

 

1.Launch Kintari USA Inc., and generate revenue from direct sales of our cosmeceutical product line;

 

2.Capitalize on the success of current licensees;

 

3.Increase the value of our current pipeline; and

 

4.Boost licensing revenues by securing additional licensees globally and develop a robust royalty revenue stream that will finance our future growth.

 

1.Launch Kintari USA Inc.:

 

 

On September 9, 2014, we formed Kinatri USA Inc., a new wholly-owned subsidiary, to market a premium line of scientifically formulated skincare products powered by our patented Invisicare® technology. As part of our strategic focus on revenue generation and creating shareholder value, Kintari USA Inc. products will be sold via network marketing. Initially the company will begin in Q4 with a soft launch followed by full hard launch in Q1 2015. The products will be sold initially in the US and then in Canada in Q2, 2015.

The Kintari product portfolio consists of anti-aging products to help fight the signs of aging. These products have been developed using proven anti-aging ingredients with scientific evidence of their effectiveness at reducing the look of fine lines and wrinkles resulting in youthful looking skin. These potent ingredients will be powered by patented Invisicare technology, providing consumers with unique, effective products which we believe cannot be duplicated. Additional products will be added to enhance this product line as the company grows and expands.

 

5

 

2.Capitalize On Current Licensees:

 

We have licensees around the globe. Three of these licensees are currently in the marketplace: Avon Products globally, Women’s Choice Pharmaceuticals in the United States and Alto Pharmaceuticals in Canada.

 

We continue to work diligently with our licensees to ensure they have a smooth manufacturing process, ongoing R&D support and marketing feedback.

 

Avon Products, Inc:

Product: We have a long-term contract with Avon globally for over ten years to provide Invisicare polymer for their long-lasting lipsticks.

 

Sales: Invisicare polymers are purchased directly from Skinvisible.

 

 

 

Alto Pharmaceuticals:

Product: DermSafe®, long lasting hand sanitizer lotion was launched in Canada in Q4 of 2011 for commercial / industrial use. The company has canceled the license agreement with Alto and will now be pursuing sales through its’ new subsidiary Kintari.

 

 

 

 

 

 

 

 

 

Women’s Choice Pharmaceuticals:

Product: ProCort®, long lasting prescription hemorrhoid cream launched in the United States August 2011.

 

Sales and Royalties: Skinvisible receives a royalty based on net sales of ProCort. This past year Women's Choice Pharmaceuticals LLC partnered with Advanced Medical Enterprises, LLC to market ProCort® in Puerto Rico. With over thirty pharmaceutical sales reps calling on OBGYNs in the US, Women’s Choice has been successfully growing their sales of ProCort® and we look forward to increased growth in 2014 and 2015. Women’s Choice is seeking to form other strategic alliances in order to increase its sales efforts by targeting new territories and targeting medical specialists which previously were not called upon.

 

6

 

Product Updates:

 

We have additional information on specific products which add value to Skinvisible’s product pipeline.

 

DermSafe® Hand Sanitizer

Skinvisible’s hand sanitizer formulated with Invisicare® and chlorhexidine gluconate has received registration in Belgium on behalf of Skinvisible. This registration allows Skinvisible to make DermSafe® available in most of Europe through a simple registration process. The Company is currently seeking licensees and/or distributors to begin the sale of DermSafe in the EU. This registration has recently been granted for a ten year term to expire in 2024.

 

US PATENT #8,735,422: “Cationic Pharmaceutically Active Ingredient Containing Composition and Methods for Manufacturing and Using”: In May we announced that Skinvisible has been granted a new patent by the United States Patent and Trademark Office. The patent provides formulation protection until April 2030 and covers the composition of formulations developed with cationic actives such as imiquimod (used for certain skin cancers: actinic keratosis (precancerous skin lesions), superficial basal cell carcinoma (sBCC) and external genital warts), terbinafine and miconazole (anti-fungals used to treat athletes foot, jock itch, ringworm, and other fungal infections of the skin) in combination with Skinvisible’s proprietary polymer delivery system, Invisicare. Additionally, Skinvisible has filed a divisional patent application seeking further claims.

 

Sunless Tanning Products: During the past few months we have developed a new sunless tanning mousse / foam which uses a unique foam with Invisicare®, developed specifically for its foaming properties. This adds to Skinvisible’s line of sunless tanning products which includes sunless tanning lotions (light, medium and dark), pre-sun moisturizer and after-sun moisturizer along with sunless tanning spray products for commercial use. The addition of a sunless tanning mousse enhances this line of products which are available for exclusive licensing.

 

We completed our first production of our patented broad spectrum sunscreen. Skinvisible’s sunscreens with SPF 15, 30 and 50 (the highest SPF allowed by the FDA) are formulated with Avobenzone, the only UVA sun filter allowed under the US FDA monograph. This UVA/UVB sunscreen was granted a patent from the United States patent office last year. Avobenzone is known for breaking down in the sun after only two hours – thus the requirement to reapply every 2 hours. Skinvisible’s patent was granted based on Invisicare's® minimum 8 hour photo stability. For countries outside the United States, Skinvisible has additionally patented UVA/UVB sunscreens formulated with Tinosorb S that are available for licensing.

 

In March 25, 2014, we announced that we have successfully completed independent testing to validate our broad spectrum sunscreen claims according to new labeling guidelines by the FDA which are designed to help reduce the incidents of skin cancer in the U.S.

 

Skinvisible sunscreens can be labeled with the following claims:

 

Claim # 1 – Broad-Spectrum: According to the FDA, in order for a sunscreen to be labeled “broad spectrum” it must prove it protects against both UVA and UVB rays by having an SPF (Sun Protection Factor) of at least 15 and a critical wave length of at least 370 nm. Skinvisible’s sunscreen has surpassed both of these criteria, allowing Skinvisible’s broad spectrum sunscreen label to also state “prevents sunburn, skin cancer and aging due to the sun.”

 

Claim # 2 – Water-Resistant 80 Minutes: The FDA sunscreen water resistant claim requires that a sunscreen must have the same SPF after being in water or sweating for 40 or 80 minutes. Skinvisible’s testing was conducted at an independent laboratory specializing in sunscreen testing. The test involved human subjects that applied sunscreen to their arm, followed by the immersion of the arm into a Jacuzzi for 80 minutes (10 minutes in / 10 minutes out). Skinvisible’s sunscreen successfully completed this testing and is allowed to use “Water-resistant for 80 Minutes” on its sunscreen label, the longest length of time allowed by the FDA.

 

Claim # 3 – Unique Patented Technology / Eight-Hour Photostability: As previously announced, Skinvisible was granted a patent from the United States Patent and Trademark Office entitled “Sunscreen Composition with Enhanced UVA Absorber Stability and Methods”, which provides protection until November 2029. Skinvisible successfully formulated a unique Invisicare® delivery system specifically for stabilizing avobenzone; the key sunscreen used in the USA. Data submitted to the US patent office proved that Skinvisible’s sunscreen provides a minimum of eight hours of photostability.

 

7

 

3.Increasing The Value Of Skinvisible’s Pipeline: Clinical Enhancement Of Pipeline

 

We have a pipeline of over forty products which are available for licensing. Testing is conducted in-house generating proof of concept including release of the active ingredient as well as long term shelf life (stability). Additional studies conducted on specific products including skin sensitivity, toxicity and product efficacy are outsourced to FDA compliant laboratories. These studies are critical in attracting potential licensees. Our clinical strategy is to:

 

  • Add new studies for our prescription products. Our clinical strategy is to increase the amount of outsourced studies, specifically for our prescription products. Additional studies including skin penetration and skin irritation studies will add to the integrity and value of our products available for licensing.

  • Add new long-term efficacy studies for our DermSafe® hand sanitizer. Last year we commissioned an independent laboratory to further analyze the long-term effectiveness of DermSafe® when put in contact with two bacteria; the “super bug” MRSA and E. coli, the “restaurant bug” since it is often transmitted by food and food handlers. The long-term effectiveness of two bacteria; Methicillin-resistant Staphylococcus aureus or MRSA (ATCC #33591) and Escherichia coli or E. coli (ATCC #43888") were tested up to four hours after application. The results showed that the individual arms of subjects which had DermSafe® applied and were even rinsed prior to each bacteria challenge, showed a 95.83% reduction at the 4 hour time point for MRSA and 99.38% for E. coli. Late last year we obtained the registration rights for DermSafe® in Belgium. This designation allows for the sale and/ or registration of DermSafe in most EU countries. A strategy is being developed along with a larger global strategy to bring DermSafe to the EU and Asia in 2015. Skinvisible has also commissioned further testing of DermSafe against the (Middle East Respiratory Syndrome Coronavirus (MERS-CoV); a SARS-like virus and the avian influenza A virus, H7N9 which is presently a major health issue in China .

  • We continue to look for avenues to obtain orphan drug status for our Netherton syndrome product. Netherton syndrome. is a disease caused by a genetic defect which causes the skin to continually exfoliate, never forming a skin bond. This leaves the patient highly susceptible to infection and dealing with a life-long condition that has no cure. Our product has shown excellent results in lab studies blocking the enzyme that breaks down the skin and we are seeking “Orphan Drug” designation in both the US (FDA) and Europe (EMA).

The advantages of obtaining Orphan Drug designation is that it provides various incentives including a reduction or elimination of registration and market authorization fees, protocol assistance, and seven years of market exclusivity for the product in the US and ten years in Europe. There can be no assurances that our project will be successful.

 

  • Seek clinical partnerships which will result in FDA approvals of our prescription products. There are three “Phases” involved in obtaining FDA approval. The completion of Phase 1 and/or Phase 2 will increase the value of the license and royalty fees of our products significantly. We are also seeking partnerships with Clinical Research Organizations (CROs) in order to define and begin the regulatory pathway for one or more of our prescription products.

4.Secure Additional Licensees:

 

We are in discussions and undergoing internal studies with various global pharmaceutical and Consumer Goods companies for licenses.

 

We continue to focus on completing the (confidential) development projects that are in progress, continuing our negotiations with multi-national companies on a number of potential OTC and prescription product license agreements and advancing discussions with interested international clients regarding joint ventures.

 

To facilitate further expansion, we have entered discussions with potential partners that are dermatology service providers and knowledgeable and connected in the dermatology market.

 

Results of Operations for the Three and Nine Months Ended September 30, 2014 and 2013

 

Revenues

 

Our revenue from product sales, royalties on patent licenses and license fees for the three months ended September 30, 2014 was $22,303, an increase from $13,635 for the same period ended September 30, 2013.  Our revenue from product sales, royalties on patent licenses and license fees for the nine months ended September 30, 2014 was $41,276, a decrease from $48,370 for the same period ended September 30, 2013. 

 

The decrease in revenue for the nine months ended September 30, 2014 was mainly due to a decrease in product sales. With the launch of Kintari USA Inc., we expect increased revenue from our line of anti-aging products and select over-the-counter products.

 

8

 

Cost of Revenues

 

Our cost of revenues for the three months ended September 30, 2014 increased to $674 from the prior year period when cost of revenues was $565. Our cost of revenues for the nine months ended September 30, 2014 increased to $3,907 from the prior year period when cost of revenues was $1,754.

 

Gross Profit

 

Gross profit for the three months ended September 30, 2014 was $21,629, or approximately 96% of sales. Gross profit for the three months ended September 30, 2013 was $13,070, or approximately 96% of sales. Gross profit for the nine months ended September 30, 2014 was $37,369, or approximately 90% of sales. Gross profit for the nine months ended September 30, 2013 was $46,616, or approximately 96% of sales.

 

Operating Expenses

 

Operating expenses increased to $382,781 for the three months ended September 30, 2014 from $229,845 for the same period ended September 30, 2013. Operating expenses increased to $787,024 for the nine months ended September 30, 2014 from $643,173 for the same period ended September 30, 2013.

 

Our operating expenses for the nine months ended September 30, 2014 consisted mainly of salaries and wages of $136,318, accrued salaries and wages of $165,652, consulting fees of $182,748, research and development of $48,231, accounting and audit expenses of $30,069, rent of $31,368, depreciation and amortization expenses of $28,027, legal fees of $24,539 and travel of $19,949. In comparison, our operating expenses for the nine months ended September 30, 2013 consisted mainly of salaries and wages of $113,321, accrued salaries and wages of $157,502, consulting expenses of $153,735, accounting and audit expenses of $35,160, edgarization fees of $24,878, depreciation and amortization expenses of $27,006, travel of $15,876 and rent of $14,942.

 

Other Expenses

 

We had other expenses of $204,928 for the three months ended September 30, 2014, compared with other expenses of $123,328 for the three months ended September 30, 2013. This was largely the result of $200,944 we paid in interest expenses for the three months ended September 30, 2014 from $125,825 in the prior period ended September 30, 2013.

 

We had other expenses of $556,658 for the nine months ended September 30, 2014, compared with other expenses of $433,201 for the nine months ended September 30, 2013. This was largely the result of $551,872 we paid in interest expenses for the nine months ended September 30, 2014 from $436,398 in the prior period ended September 30, 2013.

 

We expect to continue to experience high interest payments in the future as a result of our outstanding liabilities. If we are unable to generate sufficient revenues and/or additional financing to service this debt, there is a risk the lenders will call the notes and we will be unable to repay the loans. If this happens, we could go out of business.

 

Net Loss

 

We recorded a net loss of $566,080 for the three months ended September 30, 2014, as compared with a net loss of $340,103 for the three months ended September 30, 2013. We recorded a net loss of $1,306,313 for the nine months ended September 30, 2014, as compared with a net loss of $1,029,758 for the nine months ended September 30, 2013.

 

Liquidity and Capital Resources

 

As of September 30, 2014, we had total current assets of $362,416 and total assets in the amount of $675,187. Our total current liabilities as of September 30, 2014 were $4,499,081. We had a working capital deficit of $4,136,665 as of September 30, 2014.

 

Operating activities used $820,737 in cash for the nine months ended September 30, 2014. Our net loss of $1,306,313 was the main component of our negative operating cash flow, offset mainly by amortization of debt discount of $248,518, an increase in accounts payable and accrued liabilities of $101,003 and an increase of accrued interest of $133,516.

 

Cash flows used by investing activities during the nine months ended September 30, 2014 was $15,855 as a result of the purchase of fixed and intangible assets.

 

Cash flows provided by financing activities during the nine months ended September 30, 2014 amounted to $581,478 and consisted mainly of $594,400 in proceeds from loans payable.

 

9

 

On May 19, 2014, we approved a financing plan to offer accredited investors up to an additional $1,000,000 in secured promissory notes. Through September of 2014, we entered into 9% notes payable to investors and received total proceeds of $594,400. The notes are due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods".

 

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to fund operations through increased sales and debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all.

 

Off Balance Sheet Arrangements

 

As of September 30, 2014, there were no off balance sheet arrangements.

 

Critical Accounting Policies

 

In December 2001, the SEC requested that all registrants list their most “critical accounting polices” in the Management Discussion and Analysis. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.

 

Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have incurred cumulative net losses of $25,221,121 since our inception and require capital for our contemplated operational and marketing activities to take place. Our ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of our contemplated plan of operations, and our transition, ultimately, to the attainment of profitable operations are necessary for us to continue operations. The ability to successfully resolve these factors raise substantial doubt about our ability to continue as a going concern. These consolidated financial statements do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

 

Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.

 

Royalty sales – We also recognize royalty revenue from licensing our patented product formulations only when earned, with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

 

Distribution and license rights sales – We also recognize revenue from distribution and license rights only when earned (and are amortized over a five year period), with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

 

Costs of Revenue – Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

 

Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of September 30, 2014, the Company had not recorded a reserve for doubtful accounts. The Company has $1,000,000 in convertible notes payable which are secured by the accounts receivable of a license agreement the Company has with Women's Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®.

 

Recently Issued Accounting Pronouncements

 

We do not expect the adoption of recently issued accounting pronouncements to have a significant impact on our results of operations, financial position or cash flow.

 

Item 3.     Quantitative and Qualitative Disclosures About Market Risk

 

A smaller reporting company is not required to provide the information required by this Item.

 

10

 

Item 4.     Controls and Procedures

 

Disclosure Controls and Procedures

 

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of September 30, 2014. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2014, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of September 30, 2014, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

 

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting

 

Our company plans to take steps to enhance and improve the design of our internal controls over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the following changes during our fiscal year ending December 31, 2014: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting during the three months ended September 30, 2014 that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

 

PART II – OTHER INFORMATION

 

Item 1.     Legal Proceedings

 

We are not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

 

Item 1A:  Risk Factors

 

A smaller reporting company is not required to provide the information required by this Item.

 

11

 

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds

 

The information set forth below relates to our issuances of securities without registration under the Securities Act of 1933 during the reporting period which were not previously included in a Quarterly Report on Form 10-Q or Current Report on Form 8-K.

 

On July 1, 2014, we issued 140,000 shares with a fair value of $5,614 to settle $3,600 in outstanding accounts payable.

 

On July 7, 2014, we issued 80,000 shares with a fair value of $3,400 to settle $2,400 in outstanding accounts payable.

 

On August 4, 2014, we issued 80,000 shares of common stock with a fair value of $3,400 to settle $2,400 in outstanding accounts payable due to a consultant for research and development services.

 

On August 20, 2014, we issued a warrant for 500,000 shares of common stock to a consultant – expiry 1 year. The warrant has an exercise price of $0.04 and vested immediately.

 

On September 30, 2014, we re-negotiated accrued salaries and interest for two employees. Under the terms of the agreements, $40,558 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $40,558 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of our common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.05 per share for three years after the conversion date.

 

On May 19, 2014, we approved a financing plan to offer accredited investors up to an additional $1,000,000 in secured promissory notes. Through September of 2014, we entered into 9% notes payable to investors and received total proceeds of $594,400. The notes are due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods".

 

On Oct. 17, 2014, we issued 172,000 shares to consultants for services rendered.

 

These securities were issued pursuant to Section 4(2) of the Securities Act and/or Rule 506 promulgated thereunder. The holders represented their intention to acquire the securities for investment only and not with a view towards distribution. The investors were given adequate information about us to make an informed investment decision. We did not engage in any general solicitation or advertising. We directed our transfer agent to issue the stock certificates with the appropriate restrictive legend affixed to the restricted stock.

 

Item 3.     Defaults upon Senior Securities

 

None

 

Item 4.     Mine Safety Disclosures

 

Not applicable.

 

Item 5.     Other Information

 

None

 

Item 6.      Exhibits

 

Exhibit Number Description of Exhibit
31.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101** The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 formatted in Extensible Business Reporting Language (XBRL).
**Provided herewith

 

12

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Skinvisible, Inc.
   
Date:  November 12, 2014
   
 

By: /s/ Terry Howlett

Terry Howlett

Title:   Chief Executive Officer, Chief Financial Officer and Director

 

13